Hoechst Marrion Roussel: A strong formulation - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Hoechst Marrion Roussel: A strong formulation

Sep 4, 2000

A 51% subsidiary of the $ 14.6 bn Aventis (formed with the merger of HMR AG and Rhone Poulenc), Hoechst Marion Roussel (HMR) is the fourth largest player in the domestic market with strong products and a diversified product mix. The company’s brands such as Combiflam, Daonil, Avil, Soframycin, Baralgan–M and Novalgin are household names.

Key Products
Brand % of Sales Therapeutic Category
Combiflam 13.0% Anti–inflammatory
Daonil (Oral) 12.0% Anti–diabetic
Avil 10.0% Anti–allergic
Soframycin 7.0% Topical antibiotic
Novalgin/Baralgan M 13.0% Analgesic
Trental/Cardace 10.0% Cardiovascular
Hostacycline 4.0% Antibiotic

The company has had an indifferent performance over the last few year’s primarily due to the restructuring that the management had undertaken after the merger with Roussel. It closed down two of its plants in high cost Mumbai and shifted to relatively low cost areas such as Goa (formulations plant) and Ankleshwar (bulk drugs production). It discontinued with more than a dozen old products and sold off tailend brands such Haemaccel and Omnatax to Nicholas Piramal. This helped it fund the Voluntary Retirement Scheme (VRS) payments to the workers of the two plants based in Mumbai.

Simultaneously HMR’s parent allowed it access to new products which the latter introduced in the country. HMR introduced new products such as Cardace (cardiovascular) Amaryl (an oral anti–diabetic), Cefrom (antibiotic) Frisium (anti–epileptic) etc. over the last two years which have been well received in the Indian market.

The hugely profitable exports to Russia have also restarted in the current year though they are no where near the levels they were a couple of year’s ago.

All these measures have helped the company post a 35% growth in its bottomline in FY2000 despite a 1.4% rise in the turnover. This is primarily due to the fact that almost 60% of its revenues accrue from products that are under price control. With new products being out of price control we expect the company to report a 10% increase in the topline for FY2001.

With the restructuring almost over and the costs of restructuring written off, the company’s bottomline is likely to grow much faster in the coming years. The stock currently quotes at a price of Rs 442 (52 week range: Rs 1340/357), which implies a multiple 27.5 times FY2001 earnings.

Equitymaster requests your view! Post a comment on "Hoechst Marrion Roussel: A strong formulation ". Click here!

  

More Views on News

SANOFI INDIA 2019-20 Annual Report Analysis (Annual Result Update)

Oct 25, 2021 | Updated on Oct 25, 2021

Here's an analysis of the annual report of SANOFI INDIA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

6 Penny Stocks that Rallied 1,000%+ in One Year (Views On News)

Dec 6, 2021

These penny stocks shed their penny status by surging 1,000% or more in the last one year.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Dec 8, 2021 11:15 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - WINDLAS BIOTECH COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS